Chemotherapy + Cross-over to Osimertinib
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anticancer Treatment
Conditions
Anticancer Treatment
Trial Timeline
Aug 4, 2014 → Dec 15, 2023
NCT ID
NCT02151981About Chemotherapy + Cross-over to Osimertinib
Chemotherapy + Cross-over to Osimertinib is a phase 3 stage product being developed by AstraZeneca for Anticancer Treatment. The current trial status is completed. This product is registered under clinical trial identifier NCT02151981. Target conditions include Anticancer Treatment.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02151981 | Phase 3 | Completed |